OmniAb (OABI) Change in Receivables (2022 - 2026)
OmniAb (OABI) reported Change in Receivables of $4.9 million for Q1 2026, up 947.23% year-over-year from $470000.0 in Q1 2025, and up 125.78% on a QoQ basis from $2.2 million in Q4 2025.
OmniAb (OABI) has 5 years of Change in Receivables data on file, last reported at $4.9 million in Q1 2026.
- Quarterly Change in Receivables rose 947.23% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 million (up 247.43% YoY) and the FY2025 annual result came in at -$189000.0, down 130.24% from the prior year.
- Change in Receivables climbed to $4.9 million in Q1 2026 per OABI's latest filing, from $2.2 million in the prior quarter.
- Across five years, Change in Receivables topped out at $30.3 million in Q4 2022 and bottomed at -$28.8 million in Q1 2023.
- The 5-year median for Change in Receivables is $230000.0 (2025), against an average of -$517823.5.
- Peak annual rise in Change in Receivables reached 1533.43% in 2023, while the deepest fall reached 437.85% in 2023.
- Tracing OABI's Change in Receivables over 5 years: stood at $30.3 million in 2022, then plunged by 106.55% to -$2.0 million in 2023, then soared by 195.02% to $1.9 million in 2024, then climbed by 15.47% to $2.2 million in 2025, then surged by 125.78% to $4.9 million in 2026.
- Per Business Quant, the three latest OABI Change in Receivables figures stand at $4.9 million (Q1 2026), $2.2 million (Q4 2025), and $230000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -1.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 110.42 Mn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | 4.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.92 Mn |
| Mar 31, 2026 | 4.92 Mn |
| Dec 31, 2025 | 2.18 Mn |
| Dec 31, 2025 | 2.18 Mn |
| Sep 30, 2025 | 230,000.00 |
| Sep 30, 2025 | 230,000.00 |
| Jun 30, 2025 | -3.07 Mn |
| Jun 30, 2025 | -3.07 Mn |
| Mar 31, 2025 | 470,000.00 |
| Mar 31, 2025 | 470,000.00 |
| Dec 31, 2024 | 1.89 Mn |
| Dec 31, 2024 | 1.89 Mn |
| Sep 30, 2024 | -3.86 Mn |
| Sep 30, 2024 | -3.86 Mn |
| Jun 30, 2024 | 2.73 Mn |
| Jun 30, 2024 | 2.73 Mn |
| Mar 31, 2024 | -132,000.00 |
| Mar 31, 2024 | -132,000.00 |
| Dec 31, 2023 | -1.99 Mn |
| Dec 31, 2023 | -1.99 Mn |
| Sep 30, 2023 | -1.90 Mn |
| Sep 30, 2023 | -1.90 Mn |
| Jun 30, 2023 | 5.82 Mn |
| Jun 30, 2023 | 5.82 Mn |
| Mar 31, 2023 | -28.82 Mn |
| Mar 31, 2023 | -28.82 Mn |
| Dec 31, 2022 | 30.35 Mn |
| Dec 31, 2022 | 30.35 Mn |
| Sep 30, 2022 | -354,000.00 |
| Sep 30, 2022 | -354,000.00 |
| Jun 30, 2022 | 356,000.00 |
| Jun 30, 2022 | 356,000.00 |
| Mar 31, 2022 | -17.61 Mn |
| Mar 31, 2022 | -17.61 Mn |